Chemotherapy and radiotherapy in locally advanced cervical XXXX .

@entity1 @entity8 @entity137 @entity390 @entity3480 @entity5 @entity900 @entity391 @entity1544 @entity1732 @entity1499
Radiotherapy has been standard therapy for locally advanced @entity1544 . Neoadjuvant chemotherapy is being studied to improve responses and survival. We report a phase II study in locally advanced @entity1544 (FIGO stages III and @entity3480 ) using chemotherapy with @entity1732 , @entity1499 and @entity900 (BMP) followed by radical radiotherapy. Of the 35 @entity1 , 31 in stage III and 4 in stage @entity3480 , 3 complete responses (CR) and 22 partial responses (PR) were achieved after chemotherapy treatment. Thirty-one @entity1 completed radiotherapy; 19 achieved CR and 4 PR. Five-year actuarial survival for the entire group was 45% (95% confidence interval, 37-53%) with a median survival of 56 months. @entity1 with CR had a significantly better survival: the 5-year actuarial survival was 74% (95% CI, 59-89%). Recurrence developed in 4 of 19 @entity1 . The most frequent side-effects were @entity390 and @entity391 . Myelosuppression and @entity8 also occurred. There was no evidence of radiotherapy @entity137 enhancement. The stage and Karnofsky index were significant prognostic factors. It is concluded that BMP chemotherapy in advanced cervical @entity5 is effective and, followed by radiotherapy, allows a good control of this @entity5 . The group of @entity1 with complete response have a low rate of recurrences and a long survival chance.
